ArticleOrthopaedic surgery2025
The Effects of Denosumab Treatment on Pain and Function Beyond Bone Density in Patients With Postmenopausal Osteoporosis: A Prospective Study.
Article in Orthopaedic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular Mechanisms and Therapeutic Targets for Pain Following Osteoporotic Vertebral Fractures.Journal of pain research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectivePostmenopausal osteoporosis (PMOP) leads to bone loss, fragility, and fractures, causing pain and reduced function. Effective treatment should improve bone mineral density (BMD), prevent fractures, and enhance quality of life. Denosumab is FDA-approved for osteoporosis, but its effects on pain and function in Chinese patients with PMOP remain underexplored. This study investigates the impact and influencing factors of denosumab treatment on pain and function to support a broader evaluation of osteoporosis treatment.
methodsThis prospective study included 200 patients with PMOP, treated at the hospital, between September 2022 and September 2023. Subjects received 60 mg of denosumab subcutaneously, and calcium and vitamin D supplements. Pain (Numerical Rating Scale, NRS), function (Oswestry Disability Index, ODI), bone metabolic markers, and BMD were assessed at baseline, 6, and 12 months posttreatment. Correlations between NRS, ODI, and BMD, and the influencing factors of efficacy differences were analyzed.
results(1) Posttreatment, NRS scores and ODI significantly decreased. (2) Posttreatment, bone metabolic markers were significantly lower; BMD of the hip, femoral neck, and lumbar spine significantly increased from baseline but was most significant in the lumbar spine. (3) Changes in NRS and ODI positively correlated with the increase in lumbar spine BMD but not with changes in femoral neck or total hip BMD. ODI reduction was positively correlated with increases in all three sites' BMD. (4) Factors influencing NRS, ODI, and BMD of treatment include the following: patients with prior fragility fractures (mainly vertebral fractures) had greater improvements in NRS, ODI, and lumbar spine BMD than those without a history of fragility fractures; those without previous antiosteoporosis medication had a more significant increase in lumbar spine BMD than those with a history of antiosteoporosis medication use (mainly antiresorptive drugs).
conclusionFollowing 12 months of denosumab treatment in patients with PMOP and increasing BMD, there was a significant improvement in pain and functional disability. The improvement in pain was closely related to the increase in lumbar spine BMD, while functional enhancement was strongly associated with BMD gains in the total hip, femoral neck, and lumbar spine. Age, weight, and osteoporosis severity do not affect treatment response. Patients with prior fragility fractures (mainly vertebral fractures) experienced more significant improvements in pain symptoms and functional outcomes. Denosumab resulted in a more significant increase in BMD in patients with a history of fragility fractures (mainly vertebral fractures) and those without a history of antiosteoporosis medication use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.